Is PALI or PCSA more undervalued in 2026?

CirclFi compares Palisade Bio, Inc. (PALI) and Processa Pharmaceuticals, Inc. (PCSA) using 13 institutional-grade valuation models. PALI has a Quality of Company score of 4.0/10 while PCSA scores 3.7/10.

Which is a better buy — PALI or PCSA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PALI and PCSA valuations compare?

PALI at $2.06 and PCSA at $2.64 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PALI vs PCSA Valuation Comparison 2026 — Intrinsic Value Analysis

PALI

Biotechnology

Palisade Bio, Inc.

Quality

4.0

out of 10

Value Trap

LOW

Price

$2.06

Last close

Models

7/13

Active

PCSA

Biotechnology

Processa Pharmaceuticals, Inc.

Quality

3.7

out of 10

Value Trap

SAFE

Price

$2.64

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	PALI Fair Value	PALI Upside	PCSA Fair Value	PCSA Upside
Bayesian DCF	Intrinsic	$0.97	-52.9%	$1.04	-60.5%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.16	-92.4%	$0.20	-93.4%
Dynamic NAV	Asset-Based	$0.86	-58.1%	$5.65	+114.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PALI vs PCSA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PALI vs PCSA — Which Stock Is More Undervalued?

PALI scores higher with a 4.0/10 quality rating vs PCSA's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Palisade Bio, Inc. (PALI) and Processa Pharmaceuticals, Inc. (PCSA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PALI currently trades at $2.06 with a QOC of 4.0/10, while PCSA trades at $2.64 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).